A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

NCT01298141 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
171
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Shire